Premium
Comparison of G‐CSF and GM‐CSF Adverse Event Profiles in Office‐Based Practices: Preliminary Study Results
Author(s) -
Moleski Ronald J.
Publication year - 2000
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.20.10.112s.35233
Subject(s) - medicine , adverse effect , granulocyte macrophage colony stimulating factor , adverse drug event , clinical practice , granulocyte colony stimulating factor , drug , granulocyte , intensive care medicine , emergency medicine , pharmacology , family medicine , chemotherapy , cytokine
We investigated the adverse event profile of colony‐stimulating factors (CSFs) used in office‐based oncology practices in the United States. The impetus for the study was anecdotal reports from physicians and nurses working in community practice settings describing the differences in adverse drug events (ADEs) that their patients experienced with the two CSFs currently available in the United States. The study was a retrospective review of office‐based oncology practice records. The frequencies of drug‐induced fever and other ADEs secondary to granulocyte (G)‐CSF were compared with those of granulocyte‐macrophage (GM)‐CSF. Adverse drug events were those events that were documented by a clinician as being causally linked to CSF therapy and not obviously due to other causes. This preliminary report of the data indicated that there were some significant differences in the ADEs attributable to either G‐CSF or GM‐CSF. The appropriate use of CSFs in clinical practice also is discussed.